Overview
Clinical Benefits
- Appetite suppression
- Daily flexibility (can pause without long washout)
- Lower price point than newer GLP-1s
- Good 'starter' GLP-1 for sensitive patients
Administration
Subcutaneous injection — abdomen, thigh, or upper arm
Drug class: glp1 agonist
Clinical Dosing
Typical dosage
Titrate to 3.0mg daily (Saxenda dose)
Starting dose
0.6mg
Cadence
Once daily
Full titration schedule
| Phase | Dose |
|---|---|
| Week 1 | 0.6mg once daily |
| Week 2 | 1.2mg once daily |
| Week 3 | 1.8mg once daily |
| Week 4 | 2.4mg once daily |
| Weeks 5+ | 3.0mg once daily (maintenance) |
Safety Profile
Side effects
- • Nausea
- • Vomiting
- • Diarrhea
- • Injection site reactions
- • Hypoglycemia (with insulin/sulfonylureas)
Contraindications
- • Pregnancy
- • MTC history
- • MEN2
- • Pancreatitis history
Do not combine with
Frequently asked questions
Liraglutide is most commonly researched for: Appetite suppression, Daily flexibility (can pause without long washout), Lower price point than newer GLP-1s, Good 'starter' GLP-1 for sensitive patients.
Ready to build a protocol with Liraglutide?
LIA, our clinical reasoning engine, will build a personalized protocol — dosing, cadence, cycling, and safety checks — tailored to your goals and intake.
You’ll be asked to sign in first. Free tier includes the chat preview.
Information on this page is for educational purposes only and is not medical advice. Peptides should only be used under the supervision of a qualified healthcare provider.